Pterin Function in Bacteria
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Folate and Pterin Metabolism by Cancer Cells in Culture1
[CANCER RESEARCH 38, 2378-2384, August 1978) 0008-5472/78/0038-0000$02.00 Folate and Pterin Metabolism by Cancer Cells in Culture1 Baldassarre Stea, Peter S. Backlund, Jr., Phillip B. Berkey, Arthur K. Cho, Barbara C. Halpern, Richard M. Halpern, and Roberts A. Smith2 Departments of Chemistry (B. S., P. S. B., P. B. B., B. C. H.¡,Pharmacology ¡A.K. C.], Medicine, ¡Ft.M. H.]. and Chemistry [Ft. A. SJ and Molecular Biology Institute ¡R.M. H., R. A. S.], University of California, Los Angeles, California 90024 ABSTRACT cells, a significant peak of radioactivity was observed in the blue-fluorescent region. This peak of radioactivity was ab Malignant cells grown in culture excrete into their sent in chromatograms of growth media of normal cells growth medium a folate catabolite that can be seen as a grown under the same conditions. blue-fluorescent region on paper chromatograms of such We tentatively identified this blue-fluorescent compound media. This folate catabolite has now been identified by as Pt-6-CHO,3 primarily on the basis of its inhibitory power paper chromatography, thin-layer chromatography, and toward xanthine oxidase. However, we later found that Pt- combined gas chromatography-mass spectrometry as 6- 6-CH2OH also is a potent inhibitor of the same enzyme hydroxymethylpterin and not as pterin-6-carboxaldehyde system. This prompted us to identify by unequivocal means as previously reported. the fluorescent folate catabolite characteristic of cultured Moreover, when pterin-6-carboxaldehyde was added to malignant cells. the growth medium of logarithmically growing malignant Here we report the definitive identification of this blue- cells, it was primarily reduced to 6-hydroxymethylpterin. -
Kohen Curriculum Vitae
Curriculum Vitae Amnon Kohen Department of Chemistry Tel: (319) 335-0234 University of Iowa FAX: (319) 335-1270 Iowa City, IA 52242 [email protected] EDUCATION AND PROFESSIONAL HISTORY Education D.Sc., Chemistry 1989-1994 Technion – Israel Institute of Technology, Haifa, Israel Advisor: Professor T. Baasov Topic: Mechanistic Studies of the Enzyme KDO8P Synthase B.Sc., Chemistry (with Honors) 1986-1989 Hebrew University, Jerusalem, Israel Positions Professor 2010-Present Department of Chemistry, University of Iowa, Iowa City, IA and Molecular and Cellular Biology Program, and MSTP faculty member Associate Professor 2005-2010 Department of Chemistry, University of Iowa, Iowa City, IA and Molecular and Cellular Biology Program Assistant Professor 1999-2005 Department of Chemistry, University of Iowa, Iowa City, IA Postgraduate Researcher 1997-1999 With Professor Judith Klinman Department of Chemistry, University of California, Berkeley Topic: Hydrogen Tunneling in Biology: Alcohol Dehydrogenases Postgraduate Fellow 1995-1997 With Professor Judith Klinman Department of Chemistry, University of California, Berkeley Topic: Hydrogen Tunneling in Biology: Glucose Oxidase Visiting Scholar Fall 1994 With Professor Karen S. Anderson Department of Pharmacology, Yale Medical School, New Haven, CT Kohen, A. Affiliations American Society for Biochemistry and Molecular Biology (ASBMB, 2013 - present) Center for Biocatalysis and Bioprocessing (CBB) University of Iowa (2000-Present) The Interdisciplinary Graduate Program in Molecular Biology, University of Iowa (2003- Present) American Association for the Advancement of Science (AAAS, 2011-present) American Chemical Society (1995-Present) Divisions: Organic Chemistry, Physical Chemistry, Biochemistry Sigma Xi (1997-Present) Protein Society (1996-1998) Honors and Awards • Career Development Award (University of Iowa- 2015-2016) • Graduate College Outstanding Faculty Mentor Award (2015). -
Molecular Cloning, Expression and Enzymatic Assay of Pteridine Reductase 1 from Iranian Lizard Leishmania
Iranian Biomedical Journal 14 (3): 97-102 (July 2010) Molecular Cloning, Expression and Enzymatic Assay of Pteridine Reductase 1 from Iranian Lizard Leishmania Bahram Kazemi*1,2, Farideh Tohidi3,4, Mojgan Bandehpour1 and Fatemeh Yarian1 1Cellular and Molecular Biology Research Center and 2Dept. of Parasitology and Mycology, Shahid Beheshti University, Tehran; 3Dept. of Parasitology and Mycology, Gorgan University of Medical Sciences, Gorgan; 4Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran Received 17 April 2010; revised 17 July 2010; accepted 24 July 2010 ABSTRACT Background: Currently, there are no effective vaccines against leishmaniasis, and treatment using pentavalent antimonial drugs is occasionally effective and often toxic for patients. The PTR1 enzyme, which causes antifolate drug resistance in Leishmania parasites encoded by gene pteridine reductase 1 (ptr1). Since Leishmania lacks pteridine and folate metabolism, it cannot synthesize the pteridine moiety from guanine triphosphate. Therefore, it must produce pteridine using PTR1, an essential part of the salvage pathway that reduces oxidized pteridines. Thus, PTR1 is a good drug-target candidate for anti-Leishmania chemotherapy. The aim of this study was the cloning, expression, and enzymatic assay of the ptr1 gene from Iranian lizard Leishmania as a model for further studies on Leishmania. Methods: Promastigote DNA was extracted from the Iranian lizard Leishmania, and the ptr1 gene was amplified using specific primers. The PCR product was cloned, transformed into Escherichia coli strain JM109, and expressed. The recombinant protein (PTR1 enzyme) was then purified and assayed. Results: ptr1 gene was successfully amplified and cloned into expression vector. Recombinant protein (PTR1 enzyme) was purified using affinity chromatography and confirmed by Western-blot and dot blot using anti-Leishmania major PTR1 antibody and anti-T7 tag monoclonal antibody, respectively. -
Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma Brucei Pteridine Reductase 1 Daniel Spinks, Han B
MED DOI: 10.1002/cmdc.201000450 Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductase 1 Daniel Spinks, Han B. Ong, Chidochangu P. Mpamhanga, Emma J. Shanks, David A. Robinson, Iain T. Collie, Kevin D. Read, Julie A. Frearson, Paul G. Wyatt, Ruth Brenk, Alan H. Fairlamb, and Ian H. Gilbert*[a] Genetic studies indicate that the enzyme pteridine reductase 1 chemistry and structure-based approaches, we were able to (PTR1) is essential for the survival of the protozoan parasite Try- derive compounds with potent activity against T. brucei PTR1 app m panosoma brucei. Herein, we describe the development and (K i = 7n ), which had high selectivity over both human and optimisation of a novel series of PTR1 inhibitors, based on ben- T. brucei dihydrofolate reductase. Unfortunately, these com- zo[d]imidazol-2-amine derivatives. Data are reported on 33 pounds displayed weak activity against the parasites. Kinetic compounds. This series was initially discovered by a virtual studies and analysis indicate that the main reason for the lack screening campaign (J. Med. Chem., 2009, 52, 4454). The inhibi- of cell potency is due to the compounds having insufficient tors adopted an alternative binding mode to those of the nat- potency against the enzyme, which can be seen from the low m m ural ligands, biopterin and dihydrobiopterin, and classical in- Km to Ki ratio (Km =25 n and Ki = 2.3 n , respectively). hibitors, such as methotrexate. Using both rational medicinal Introduction Human African trypanosomiasis (HAT) is a serious health prob- lem in sub-Saharan Africa, with an estimated 50 000 new infec- tions each year, and over 60 million people in 36 countries are at risk of infection.[1] HAT is a progressive and ultimately fatal disease. -
Relevance to Neurological Damage
Postgrad Med J: first published as 10.1136/pgmj.62.724.113 on 1 February 1986. Downloaded from Postgraduate Medical Journal (1986) 62, 113-123 Pteridines and mono-amines: relevance to neurological damage I. Smith, D.W. Howells and K. Hyland Institute ofChildHealth (University ofLondon), 30 Guilford Street, London WCIN2NR, UK. Summary: Patients with phenylalanine hydroxylase deficiency show increased concentrations of biopterins and neopterins, and reduced concentrations ofserotonin and catecholamines, when phenylalan- ine concentrations are raised. The pterin rise reflects increased synthesis of dihydroneopterin and tetrahydrobiopterin, and the amine fall a reduction in amine synthesis due to inhibition by phenylalanine of tyrosine and typtophan transport into neurones. The pterin and amine changes appear to be independent of each other and are present in the central nervous system as well as the periphery; they disappear when phenylalanine concentrations are reduced to normal. Patients with arginase deficiency show a similar amine disturbance but have normal pterin levels. The amine changes probably contribute neurological symptoms but pterin disturbance is not known to affect brain function. Patients with defective biopterin metabolism exhibit severely impaired amine synthesis due to tetrahydrobiopterin deficiency. Pterin concentrations vary with the site of the defect. Symptoms include profound hypokiesis and other features of basal ganglia disease. Neither symptoms nor amine changes are relieved by controlling phenylalanine concentrations. Patients with dihydropteridine reductase (DHPR) deficiency accumulate dihydrobiopterins and develop secondary folate deficiency which resembles that occurring in patients with defective 5,10-methylene tetrahydrofolate reductase activity. The latter disorder is also associated writh Parkinsonisn and defective amine and pterin turnover in the and a occurs in In central nervous system, demyelinating illness both disorders. -
Genome-Wide Association Study Identifies Vitamin B5 Biosynthesis As a Host Specificity Factor in Campylobacter
Genome-wide association study identifies vitamin B5 biosynthesis as a host specificity factor in Campylobacter Samuel K. Shepparda,b,1, Xavier Didelotc, Guillaume Mericb, Alicia Torralbod, Keith A. Jolleya, David J. Kellye, Stephen D. Bentleyf,g, Martin C. J. Maidena, Julian Parkhillf, and Daniel Falushh aDepartment of Zoology, University of Oxford, Oxford OX1 3PS, United Kingdom; bInstitute of Life Science, College of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom; cSchool of Public Health, St. Mary’s Campus, Imperial College London, London SW7 2AZ, United Kingdom; dDepartment of Animal Health, University of Cordoba, 14071 Cordoba, Spain; eDepartment of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, United Kingdom; fWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, United Kingdom; gDepartment of Medicine, University of Cambridge, Addenbrookes Hospital, Cambridge CB2 0SP, United Kingdom; and hMax Planck Institute for Evolutionary Anthropology, 04103 Leipzig, Germany Edited by W. Ford Doolittle, Dalhousie University, Halifax, Canada, and approved June 3, 2013 (received for review March 22, 2013) Genome-wide association studies have the potential to identify sources and locations by multilocus sequence typing (MLST) has causal genetic factors underlying important phenotypes but have shown that there is genetic differentiation among sequence types rarely been performed in bacteria. We present an association (STs) associated with different hosts (8). Among wild birds, spe- mapping method that takes into account the clonal population cific bird species most often harbor their own Campylobacter lin- structure of bacteria and is applicable to both core and accessory eages (8, 9). However, in agricultural animals, although there are genome variation. -
Dihydropteridine Reductase
John M. Whiteley et uf. : Dihydropteridine reductase Pteridines Vol. 4, 1993, pp. 159-173 Review Dihydropteridine Reductase John M. Whiteley§, Kottayil I. Varughesej:, Nguyen H. Xuong#, David A. Matthews, t and Charles E. Grimshawf §The Scripps Research Institute, La Jolla, CA 92037, USA., #University of California at San Diego, La Jolla, CA 92093-0317, U.SA., tAgouron Pharmaceuticals, Inc., San Diego, CA 92121, USA, and fThe Whittier Institute, La Jolla, CA 92037, USA. (Received August lO, 1993) Summary During the past decade numerous advances have been made in understanding the structure, mechanism and clinical properties of dihydropteridine reductase. An attempt is made here to delineate the current status of this essential enzyme by describing its structural features, its kinetic mechanism, the cloning and expression of both rat and human enzyme forms, the solution of their crystal structures, their classifica tion as members of a large family of short chain dehydrogenases, and finally a brief description is included indicating how current molecular biological applications have allowed the clinical definition of the aberrant form of phenylketonuria caused by a defective reductase. Key words: Dihydropteridine reductase, Quinonoid dihydrobiopterin, Crystal structure, Aberrant PKU, Gene expression, Mutagenesis Introduction and history in their heterocyclic nucleus of many centers for protonation, which often influence binding and reac Naturally occurring pteridines, which usually con tivity. Important metabolic functions of conjugated tain 2-amino and 4-hydroxyl substituents can be sep pteridine-mediated biological reactions include the arated into two distinct classes. One class contains one-carbon insertion reactions fundamental to pu the pterins of the folic acid series which possess rine biosynthesis (4. -
5,10-Methylenetetrahydrofolate Dehydrogenasefrom
JOURNAL OF BACTERIOLOGY, Feb. 1991, p. 1414-1419 Vol. 173, No. 4 0021-9193/91/041414-06$02.00/0 Copyright 0 1991, American Society for Microbiology Purification and Characterization of NADP+-Dependent 5,10-Methylenetetrahydrofolate Dehydrogenase from Peptostreptococcus productus Marburg GERT WOHLFARTH, GABRIELE GEERLIGS, AND GABRIELE DIEKERT* Institutfur Mikrobiologie, Universitat Stuttgart, Azenbergstrasse 18, D-7000 Stuttgart 1, Federal Republic of Germany Received 19 June 1990/Accepted 7 December 1990 The 5,10-methylenetetrahydrofolate dehydrogenase of heterotrophicaily grown Peptostreptococcus productus Marburg was purified to apparent homogeneity. The purified enzyme catalyzed the reversible oxidation of methylenetetrahydrofolate with NADP+ as the electron acceptor at a specific activity of 627 U/mg of protein. The Km values for methylenetetrahydrofolate and for NADP+ were 27 and 113 ,M, respectively. The enzyme, which lacked 5,10-methenyltetrahydrofolate cyclohydrolase activity, was insensitive to oxygen and was thermolabile at temperatures above 40C. The apparent molecular mass of the enzyme was estimated by gel filtration to be 66 kDa. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed the presence of a single subunit of 34 kDa, accounting for a dimeric a2 structure of the enzyme. Kinetic studies on the initial reaction velocities with different concentrations of both substrates in the absence and presence of NADPH as the reaction product were interpreted to indicate that the enzyme followed a sequential reaction mechanism. After gentle ultracentrifugation of crude extracts, the enzyme was recovered to >95% in the soluble (supernatant) fraction. Sodium (10 FM to 10 mM) had no effect on enzymatic activity. The data were taken to indicate that the enzyme was similar to the methylenetetrahydrofolate dehydrogenases of other homoacetogenic bacteria and that the enzyme is not involved in energy conservation of P. -
One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening†
4454 J. Med. Chem. 2009, 52, 4454–4465 DOI: 10.1021/jm900414x One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening† Chidochangu P. Mpamhanga, Daniel Spinks, Lindsay B. Tulloch, Emma J. Shanks, David A. Robinson, Iain T. Collie, Alan H. Fairlamb, Paul G. Wyatt, Julie A. Frearson, William N. Hunter, Ian H. Gilbert, and Ruth Brenk* Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K. Received March 31, 2009 The enzyme pteridine reductase 1 (PTR1) is a potential target for new compounds to treat human African trypanosomiasis. A virtual screening campaign for fragments inhibiting PTR1 was carried out. Two novel chemical series were identified containing aminobenzothiazole and aminobenzimidazole scaffolds, respectively. One of the hits (2-amino-6-chloro-benzimidazole) was subjected to crystal structure analysis and a high resolution crystal structure in complex with PTR1 was obtained, confirming the predicted binding mode. However, the crystal structures of two analogues (2-amino- benzimidazole and 1-(3,4-dichloro-benzyl)-2-amino-benzimidazole) in complex with PTR1 revealed two alternative binding modes. In these complexes, previously unobserved protein movements and water-mediated protein-ligand contacts occurred, which prohibited a correct prediction of the binding modes. On the basis of the alternative binding mode of 1-(3,4-dichloro-benzyl)-2-amino-benzimidazole, derivatives -
Evidence of Pyrimethamine and Cycloguanil Analogues As Dual Inhibitors of Trypanosoma Brucei Pteridine Reductase and Dihydrofolate Reductase
pharmaceuticals Article Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase Giusy Tassone 1,† , Giacomo Landi 1,†, Pasquale Linciano 2,† , Valeria Francesconi 3 , Michele Tonelli 3 , Lorenzo Tagliazucchi 2 , Maria Paola Costi 2 , Stefano Mangani 1 and Cecilia Pozzi 1,* 1 Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018–2022, University of Siena, via Aldo Moro 2, 53100 Siena, Italy; [email protected] (G.T.); [email protected] (G.L.); [email protected] (S.M.) 2 Department of Life Science, University of Modena and Reggio Emilia, via Campi 103, 41125 Modena, Italy; [email protected] (P.L.); [email protected] (L.T.); [email protected] (M.P.C.) 3 Department of Pharmacy, University of Genoa, Viale Benedetto XV n.3, 16132 Genoa, Italy; [email protected] (V.F.); [email protected] (M.T.) * Correspondence: [email protected]; Tel.: +39-0577-232132 † These authors contributed equally to this work. Abstract: Trypanosoma and Leishmania parasites are the etiological agents of various threatening Citation: Tassone, G.; Landi, G.; neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, Linciano, P.; Francesconi, V.; Tonelli, and various types of leishmaniasis. Recently, meaningful progresses in the treatment of HAT, due to M.; Tagliazucchi, L.; Costi, M.P.; Trypanosoma brucei (Tb), have been achieved by the introduction of fexinidazole and the combination Mangani, S.; Pozzi, C. Evidence of therapy eflornithine–nifurtimox. Nevertheless, due to drug resistance issues and the exitance of Pyrimethamine and Cycloguanil animal reservoirs, the development of new NTD treatments is still required. -
How Do Bacterial Cells Ensure That Metalloproteins Get the Correct Metal?
REVIEWS How do bacterial cells ensure that metalloproteins get the correct metal? Kevin J. Waldron and Nigel J. Robinson Abstract | Protein metal-coordination sites are richly varied and exquisitely attuned to their inorganic partners, yet many metalloproteins still select the wrong metals when presented with mixtures of elements. Cells have evolved elaborate mechanisms to scavenge for sufficient metal atoms to meet their needs and to adjust their needs to match supply. Metal sensors, transporters and stores have often been discovered as metal-resistance determinants, but it is emerging that they perform a broader role in microbial physiology: they allow cells to overcome inadequate protein metal affinities to populate large numbers of metalloproteins with the right metals. It has been estimated that one-quarter to one-third of all Both monovalent (cuprous) copper, which is expected proteins require metals, although the exploitation of ele- to predominate in a reducing cytosol, and trivalent ments varies from cell to cell and has probably altered over (ferric) iron, which is expected to predominate in an the aeons to match geochemistry1–3 (BOX 1). The propor- oxidizing periplasm, are also highly competitive, as are tions have been inferred from the numbers of homologues several non-essential metals, such as cadmium, mercury of known metalloproteins, and other deduced metal- and silver6 (BOX 2). How can a cell simultaneously contain binding motifs, encoded within sequenced genomes. A some proteins that require copper or zinc and others that large experimental estimate was generated using native require uncompetitive metals, such as magnesium or polyacrylamide-gel electrophoresis of extracts from iron- manganese? In a most simplistic model in which pro- rich Ferroplasma acidiphilum followed by the detection of teins pick elements from a cytosol in which all divalent metal in protein spots using inductively coupled plasma metals are present and abundant, all proteins would bind mass spectrometry4. -
MOCS2 Gene Molybdenum Cofactor Synthesis 2
MOCS2 gene molybdenum cofactor synthesis 2 Normal Function The MOCS2 gene provides instructions for making two different proteins, MOCS2A and MOCS2B, which combine to form an enzyme called molybdopterin synthase. Molybdopterin synthase performs the second of a series of reactions in the formation ( biosynthesis) of a molecule called molybdenum cofactor. Molybdenum cofactor, which contains the element molybdenum, is essential to the function of several enzymes called sulfite oxidase, aldehyde oxidase, xanthine dehydrogenase, and mitochondrial amidoxime reducing component (mARC). These enzymes help break down (metabolize) different substances in the body, some of which are toxic if not metabolized. Health Conditions Related to Genetic Changes Molybdenum cofactor deficiency MOCS2 gene mutations cause a disorder called molybdenum cofactor deficiency. This disorder is characterized by seizures that begin early in life and brain dysfunction that worsens over time (encephalopathy); the condition is usually fatal by early childhood. At least a dozen mutations in the MOCS2 gene have been found to cause a form of the disorder designated type B or complementation group B. The MOCS2 gene mutations involved in molybdenum cofactor deficiency likely eliminate the function of MOCS2A, MOCS2B, or both, although in rare cases that are less severe, some protein function may remain. Without either piece of molybdopterin synthase, molybdenum cofactor biosynthesis is impaired. Loss of the cofactor impedes the function of the metabolic enzymes that rely on it. The resulting loss of enzyme activity leads to buildup of certain chemicals, including sulfite, S-sulfocysteine, xanthine, and hypoxanthine, and low levels of another chemical called uric acid. (Testing for these chemicals can help in the diagnosis of this condition.) Sulfite, which is normally broken down by sulfite oxidase, is toxic, especially to the brain.